Anti-PD-L1 Antibody Enhances T Cell Immune Responses and Reduces Resistance of Breast Cancer Cells to Radiotherapy

Figure 5

Anti-PD-L1 antibody combined with radiotherapy facilitates T cell immune response in miR-21^+/+ mice in vivo. miR-21^+/+ mice were either treated or not treated with radiotherapy or radiotherapy+anti-PD-L1 antibody. (a) The number of CD3⁺CD8⁺ cells in the peripheral blood of miR-21^+/+ mice following different treatment protocols detected by flow cytometry. (b) T lymphocyte apoptosis rate in peripheral blood of miR-21^+/+ mice following different treatment protocols measured using Annexin V-FITC/PI. (c) Levels of IL-2 in the peripheral blood of miR-21^+/+ mice following different treatment protocols measured using ELISA. (d) Levels of IFN-γ in peripheral blood of miR-21^+/+ mice following different treatment protocols measured using ELISA. compared with miR-21^+/+ mice without treatment; ^# compared with miR-21^+/+ mice treated with radiotherapy or anti-PD-L1 antibody. Each sample was evaluated three times independently. Data () from two groups were compared using independent sample -test. The experiments were repeated 3 times independently.

(a)

(b)

(c)

(d)